N-acylethanolamine-hydrolysing acid amidase: A new potential target to treat paclitaxel-induced neuropathy

Wisam Toma, Martial Caillaud, Nipa H Patel, Tammy H Tran, Giulia Donvito, Jane Roberts, Deniz Bagdas, Asti Jackson, Aron Lichtman, David A Gewirtz, Alexandros Makriyannis, Michael S Malamas, M Imad Damaj. Eur J Pain. 2021 Jul;25(6):1367-1380.

Laboratory studyOther animals

Design

Laboratory study

Subjects

Mice with paclitaxel-induced peripheral neuropathy; lung tumour cells for cytotoxicity testing

Dose used in the study

Repeated palmitoylethanolamide, and the NAAA inhibitor AM9053 given acutely or repeatedly; doses and routes not stated in the abstract

Duration

Not stated in the abstract

What was measured

Spinal cord PEA levels after paclitaxel, mechanical hypersensitivity, conditioned place preference, and paclitaxel cytotoxicity in tumour cells.

What the authors reported

This laboratory study found:

• Paclitaxel lowered PEA in the spinal cord.
• Repeated PEA partially prevented mechanical hypersensitivity.
• Acute AM9053 reversed hypersensitivity dose-dependently through PPAR-alpha.
• Repeated AM9053 fully prevented hypersensitivity without tolerance.
• AM9053 produced place preference only in paclitaxel-treated mice.
• AM9053 did not alter paclitaxel's killing of tumour cells.

Limits of this study

A mouse model; it cannot show effect in people. PEA's own effect was partial, and doses are not stated in the abstract. Funding and conflicts not stated in the abstract.

Source

PubMed 33675555 · doi:10.1002/ejp.1758

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.